Table 2.
IC50s and EC50s summary table of all experiments
| Compound | Complex | Viability (log10[M]) glucose settings | Viability (log10[M]) galactose settings | Cell death 1 × 24 h (log10[M]) | Cell death 5 × 24 h (log10[M]) | MMP(log10[M]) | Lactate production (log10[M]) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Resazurin | Resazurin | PI staining | PI staining | ||||||||
| RPTEC/TERT1 | HepG2 | RPTEC/TERT1 | HepG2 | HepG2 3D | HepG2 3D | RPTEC/TERT1 | HepG2 | RPTEC/TERT1 | HepG2 | ||
| IC50 | IC50 | IC50 | IC50 | EC50 | EC50 | EC50 | EC50 | EC50 | EC50 | ||
| Capsaicin | CI | > − 5.00 | > − 5.00 | − 5.21 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 |
| Deguelin | CI | − 6.33 | > − 5.00 | − 6.10 | − 6.46 | − 5.41 | − 5.72 | − 5.35 | − 7.21 | − 6.62 | − 6.61 |
| Fenazaquin | CI | − 5.37 | > − 5.00 | NT | NT | NT | NT | > − 5.00 | − 6.55 | − 6.06 | − 6.07 |
| Fenpyroximate | CI | − 6.73 | > − 5.00 | − 6.65 | − 7.28 | − 6.52 | − 6.56 | − 6.36 | − 8.05 | − 6.69 | − 6.88 |
| Pyridaben | CI | − 6.12 | > − 5.00 | NT | NT | NT | NT | − 5.46 | − 8.19 | − 6.56 | − 6.85 |
| Pyrimidifen | CI | − 6.93 | > − 5.00 | − 6.88 | − 7.29 | − 5.80 | − 5.82 | − 6.57 | − 8.43 | − 6.79 | − 7.01 |
| Rotenone | CI | − 6.77 | > − 5.00 | − 6.79 | − 7.23 | − 5.89 | − 6.54 | − 7.29 | − 8.09 | − 6.65 | − 6.90 |
| Tebufenpyrad | CI | − 6.78 | > − 5.00 | − 5.94 | − 6.15 | > − 5.00 | − 5.13 | − 5.44 | − 7.29 | − 6.05 | − 6.84 |
| Carboxine | CII | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | − 6.92 |
| Fenfuram | CII | > − 5.00 | > − 5.00 | NT | NT | NT | NT | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 |
| Flutolanil | CII | > − 5.00 | > − 5.00 | NT | NT | NT | NT | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 |
| Mepronil | CII | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 |
| Thifluzamide | CII | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | − 5.06 | > − 5.00 | > − 5.00 |
| Antimycin A | CIII | − 6.92 | > − 5.00 | − 7.15 | − 7.53 | > − 5.00 | − 7.13 | − 7.36 | − 8.21 | − 6.68 | − 6.25 |
| Azoxystrobin | CIII | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | − 5.55 | − 5.70 | − 5.64 | − 5.28 |
| Cyazofamid | CIII | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | − 5.70 | > − 5.00 | − 5.42 | > − 5.00 |
| Fenamidone | CIII | > − 5.00 | > − 5.00 | NT | NT | NT | NT | > − 5.00 | − 5.50 | − 5.83 | − 5.36 |
| Kresoxim-methyl | CIII | > − 5.00 | > − 5.00 | NT | NT | NT | NT | > − 5.00 | > − 5.00 | > − 5.00 | − 6.69 |
| Picoxystrobin | CIII | − 5.47 | > − 5.00 | − 5.32 | − 5.48 | > − 5.00 | > − 5.00 | > − 5.00 | − 6.14 | − 6.32 | − 6.26 |
| Pyraclostrobin | CIII | − 5.49 | > − 5.00 | − 5.85 | − 6.04 | > − 5.00 | > − 5.00 | − 5.75 | − 6.31 | − 6.42 | − 6.32 |
| Trifloxystrobin | CIII | > − 5.00 | > − 5.00 | NT | NT | NT | NT | > − 5.00 | > − 5.00 | − 5.54 | > − 5.00 |
| Compound | ECAR basal (log10[M]) intact cells | OCR basal (log10[M]) intact cells | OCR maximal (log10[M]) intact cells | OCR basal (log10[M]) permeabilized cells | |||||
|---|---|---|---|---|---|---|---|---|---|
| RPTEC/TERT1 | HepG2 | RPTEC/TERT1 | HepG2 | RPTEC/TERT1 | HepG2 | HepG2 (IC50) | |||
| EC50 | EC50 | IC50 | IC50 | IC50 | IC50 | CI | CII/CIII | CIV | |
| Capsaicin | > − 5.00 | − 5.04 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | − 3.59 | NR | NR |
| Deguelin | − 6.71 | − 6.45 | − 6.44 | − 6.17 | − 7.02 | − 6.77 | − 6.98 | NR | NR |
| Fenazaquin | − 6.05 | − 5.62 | − 5.84 | − 5.59 | − 6.44 | − 6.42 | − 6.74 | NR | NR |
| Fenpyroximate | − 5.90 | − 6.28 | − 6.27 | − 6.17 | − 5.93 | − 6.53 | − 7.72 | NR | NR |
| Pyridaben | − 5.81 | − 5.31 | − 5.91 | − 5.49 | − 6.40 | − 5.82 | − 7.37 | NR | NR |
| Pyrimidifen | − 7.18 | − 7.29 | − 6.22 | − 7.10 | − 7.48 | − 7.61 | − 8.15 | NR | NR |
| Rotenone | − 6.76 | − 6.67 | − 6.49 | − 6.62 | − 6.99 | − 7.22 | − 7.48 | NR | NR |
| Tebufenpyrad | − 6.15 | − 6.49 | − 5.79 | − 6.07 | − 6.61 | − 6.68 | − 5.26 | > − 5.00 | NR |
| Carboxine | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 4.30 | − 4.63 | NR |
| Fenfuram | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 3.30 | > − 3.30 | NR |
| Flutolanil | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | NR | − 4.16 | > − 3.30 |
| Mepronil | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 3.30 | − 3.75 | NR |
| Thifluzamide | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | NR | − 4.71 | NR |
| Antimycin A | − 7.46 | − 7.55 | − 7.44 | − 7.55 | − 7.62 | − 7.69 | − 7.58 | − 7.72 | NR |
| Azoxystrobin | − 5.14 | > − 5.00 | − 5.04 | > − 5.00 | − 5.20 | > − 5.00 | − 4.50 | − 4.77 | > − 4.00 |
| Cyazofamid | − 5.88 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | > − 5.00 | NR | NR | NR |
| Fenamidone | − 5.37 | − 5.08 | − 5.09 | − 5.14 | − 5.35 | − 5.21 | − 4.16 | − 4.71 | NR |
| Kresoxim-methyl | − 5.28 | > − 5.00 | − 5.01 | − 5.04 | − 5.02 | > − 5.00 | − 5.25 | − 5.21 | NR |
| Picoxystrobin | − 5.88 | − 5.04 | − 5.35 | − 5.63 | − 5.77 | − 5.30 | − 5.16 | − 5.40 | NR |
| Pyraclostrobin | − 6.12 | − 5.93 | − 5.90 | − 5.86 | − 6.22 | − 5.76 | − 6.07 | − 6.41 | NR |
| Trifloxystrobin | − 5.42 | > − 5.00 | − 5.39 | > − 5.00 | − 5.37 | > − 5.00 | − 5.24 | − 5.27 | > − 4.00 |
Inhibitory and effective derived concentrations relative to all performed experiments. IC50s values were calculated with the in vitro toxicology on-line tool provided by the group of Prof. Leist, University of Konstanz (Krebs et al. 2020), which calculates the curve fit applying a 4-parameter Hill model to the re-normalized datasets. The equation of the Hill model was solved for f(x) = 50% to determine the IC50s referring to the concentrations at which an inhibitory effect of 50% was observed. For endpoints increasing with treatment, EC50s values were calculated by fitting the curve without using a model but using a point-to-point curve fit of re-normalized datasets. 1000 points were calculated with the X values ranging from lower to highest tested concentration. EC50s values were extrapolated from the curve and correspond to the concentrations at which an increased response of 50% was observed
NT not tested, NR no response